![](/images/png/glyphicons-368-expand.png)
![](/images/png/glyphicons-791-one-day.png)
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Alethia Young Reiterated (ASND) at Buy with Increased Target to $201 on, Apr 20th, 2020
Alethia Young of Cantor Fitzgerald, Reiterated "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $185 to $201 on, Apr 20th, 2020.
Alethia has made no other calls on ASND in the last 4 months.
There is 1 other peer that has a rating on ASND. Out of the 1 peers that are also analyzing ASND, 0 agree with Alethia's Rating of Hold.
This is the rating of the analyst that currently disagrees with Alethia
- David Lebovitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $180 on, Thursday, April 2nd, 2020